Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;10(3):246-260.
doi: 10.2174/1570164611310030007.

Anti-cancer Therapies in High Grade Gliomas

Cristiana Pistol Tanase  1 , Ana-Maria Enciu, Simona Mihai, Ana Iulia Neagu, Bogdan Calenic, Maria Linda Cruceru
Affiliations
Free PMC article

Anti-cancer Therapies in High Grade Gliomas

Cristiana Pistol Tanase et al. Curr Proteomics. 2013 Sep.
Free PMC article

Abstract

High grade gliomas represent one of the most aggressive and treatment-resistant types of human cancer, with only 1-2 years median survival rate for patients with grade IV glioma. The treatment of glioblastoma is a considerable therapeutic challenge; combination therapy targeting multiple pathways is becoming a fast growing area of research. This review offers an up-to-date perspective of the literature about current molecular therapy targets in high grade glioma, that include angiogenic signals, tyrosine kinase receptors, nodal signaling proteins and cancer stem cells related approaches. Simultaneous identification of proteomic signatures could provide biomarker panels for diagnostic and personalized treatment of different subsets of glioblastoma. Personalized medicine is starting to gain importance in clinical care, already having recorded a series of successes in several types of cancer; nonetheless, in brain tumors it is still at an early stage.

Keywords: Antiangiogenic therapy; PI-3K.; cancer stem cells; glioma; microRNA; personalized medicine.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
RTK-PI-3K and Notch molecular therapeutical targets in glioblastoma. EGFR – epidermal growth factor receptor; PDGFR – platelet-derived growth factor receptor; VEGFR – vascular endothelial growth factor receptor; TKIs – Tyrosine kinase inhibitors
See this image and copyright information in PMC

References

    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol . 2007;114(2):97–109. - PMC - PubMed
    1. Stupp R, Mason WP, vandenBent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med . 2005;352(10):987–996. - PubMed
    1. Hide T, Takezaki T, Nakamura H, Kuratsu J, Kondo T. Brain tumor stem cells as research and treatment targets. Brain Tumor Pathol. . 2008; 25(2):67–72. - PubMed
    1. Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme a prospective randomized clinical trial. J. Clin. Oncol . 2004;22(9):1583–1588. - PubMed
    1. Tallet AV, Azria D, Barlesi F, Spano JP, Carpentier AF, Goncalves A, Metellus P. Neurocognitive function impairment after whole brain radiotherapy for brain metastases actual assessment. Radiat. Oncol. . 2012;7(77):1–8. - PMC - PubMed

LinkOut - more resources